166 related articles for article (PubMed ID: 19328469)
1. Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis.
Vercellini P; Barbara G; Somigliana E; Bianchi S; Abbiati A; Fedele L
Fertil Steril; 2010 May; 93(7):2150-61. PubMed ID: 19328469
[TBL] [Abstract][Full Text] [Related]
2. Sexual function in first-time contraceptive ring and contraceptive patch users.
Gracia CR; Sammel MD; Charlesworth S; Lin H; Barnhart KT; Creinin MD
Fertil Steril; 2010 Jan; 93(1):21-8. PubMed ID: 18976753
[TBL] [Abstract][Full Text] [Related]
3. [Combined hormonal contraception in cycles artificially extended].
Bustillos-Alamilla E; Zepeda-Zaragoza J; Hernández-Ruiz MA; Briones-Landa CH
Ginecol Obstet Mex; 2010 Jan; 78(1):37-45. PubMed ID: 20931801
[TBL] [Abstract][Full Text] [Related]
4. Treatment of symptomatic rectovaginal endometriosis with an estrogen-progestogen combination versus low-dose norethindrone acetate.
Vercellini P; Pietropaolo G; De Giorgi O; Pasin R; Chiodini A; Crosignani PG
Fertil Steril; 2005 Nov; 84(5):1375-87. PubMed ID: 16275232
[TBL] [Abstract][Full Text] [Related]
5. Desogestrel-only contraceptive pill versus sequential contraceptive vaginal ring in the treatment of rectovaginal endometriosis infiltrating the rectum: a prospective open-label comparative study.
Leone Roberti Maggiore U; Remorgida V; Scala C; Tafi E; Venturini PL; Ferrero S
Acta Obstet Gynecol Scand; 2014 Mar; 93(3):239-47. PubMed ID: 24372517
[TBL] [Abstract][Full Text] [Related]
6. Effects of the contraceptive patch and the vaginal ring on bone metabolism and bone mineral density: a prospective, controlled, randomized study.
Massaro M; Di Carlo C; Gargano V; Formisano C; Bifulco G; Nappi C
Contraception; 2010 Mar; 81(3):209-14. PubMed ID: 20159176
[TBL] [Abstract][Full Text] [Related]
7. Extended regimens of the combined contraceptive vaginal ring containing etonogestrel and ethinyl estradiol: effects on lipid metabolism.
Barreiros FA; Guazzelli CA; Barbosa R; Torloni MR; Barbieri M; Araujo FF
Contraception; 2011 Aug; 84(2):155-9. PubMed ID: 21757057
[TBL] [Abstract][Full Text] [Related]
8. Extended regimens of the vaginal contraceptive ring: cycle control.
Guazzelli CA; Barreiros FA; Barbosa R; de Araújo FF; Moron AF
Contraception; 2009 Nov; 80(5):430-5. PubMed ID: 19835716
[TBL] [Abstract][Full Text] [Related]
9. Vaginal ring contraception.
Kerns J; Darney P
Contraception; 2011 Feb; 83(2):107-15. PubMed ID: 21237335
[TBL] [Abstract][Full Text] [Related]
10. Extended use of transdermal norelgestromin/ethinyl estradiol: a randomized trial.
Stewart FH; Kaunitz AM; Laguardia KD; Karvois DL; Fisher AC; Friedman AJ
Obstet Gynecol; 2005 Jun; 105(6):1389-96. PubMed ID: 15932834
[TBL] [Abstract][Full Text] [Related]
11. Comparing patient telephone callback rates for different hormonal birth control delivery systems.
Victor I; Fink RA
Am J Ther; 2006; 13(6):507-12. PubMed ID: 17122531
[TBL] [Abstract][Full Text] [Related]
12. Add-back therapy in the treatment of endometriosis-associated pain.
Zupi E; Marconi D; Sbracia M; Zullo F; De Vivo B; Exacustos C; Sorrenti G
Fertil Steril; 2004 Nov; 82(5):1303-8. PubMed ID: 15533351
[TBL] [Abstract][Full Text] [Related]
13. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
Jick S; Kaye JA; Li L; Jick H
Contraception; 2007 Jul; 76(1):4-7. PubMed ID: 17586129
[TBL] [Abstract][Full Text] [Related]
14. Clinical performance and menstrual bleeding patterns with three dosage combinations of a Nestorone progestogen/ethinyl estradiol contraceptive vaginal ring used on a bleeding-signaled regimen.
Weisberg E; Brache V; Alvarez F; Massai R; Mishell DR; Apter D; Gale J; Sivin I; Tsong YY; Fraser IS
Contraception; 2005 Jul; 72(1):46-52. PubMed ID: 15964292
[TBL] [Abstract][Full Text] [Related]
15. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
Jick SS; Kaye JA; Russmann S; Jick H
Contraception; 2006 Mar; 73(3):223-8. PubMed ID: 16472560
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the contraceptive efficacy, compliance, and satisfaction with the transdermal contraceptive patch system Evra: a comparison between adolescent and adult users.
Bodner K; Bodner-Adler B; Grünberger W
Arch Gynecol Obstet; 2011 Mar; 283(3):525-30. PubMed ID: 20111970
[TBL] [Abstract][Full Text] [Related]
17. Ethinylestradiol + norelgestromin: new preparation. Transdermal contraception: no tangible progress.
Prescrire Int; 2004 Aug; 13(72):123-6. PubMed ID: 15532134
[TBL] [Abstract][Full Text] [Related]
18. High acceptability and satisfaction with NuvaRing use.
Szarewski A
Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 2():31-6; discussion 37-9. PubMed ID: 12659400
[TBL] [Abstract][Full Text] [Related]
19. Bleeding patterns of women using extended regimens of the contraceptive vaginal ring.
Barreiros FA; Guazzelli CA; de Araújo FF; Barbosa R
Contraception; 2007 Mar; 75(3):204-8. PubMed ID: 17303490
[TBL] [Abstract][Full Text] [Related]
20. Comparison of uterine concentrations of ethinyl estradiol and etonogestrel after use of a contraceptive vaginal ring and an oral contraceptive.
Roumen FJ; Dieben TO
Fertil Steril; 2006 Jan; 85(1):57-62. PubMed ID: 16412731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
